Hemcheck Sweden AB has received a new follow up order from the Foundation for Innovative New Diagnostics (FIND) regarding delivery of reader and one-time tests (v-Test). The order is worth over 10,000 EUR.

-Our collaboration with FIND continues, which is very positive. We continue see good potential in the collaboration where we can help and strengthen the quality work within their large network of healthcare facilities and biobanks, says Joen Averstad, acting CEO of Hemcheck.

For further information contact:

Hemcheck Sweden AB (publ)

Joen Averstad, acting CEO

Tel: +46 76 108 8191

Email: joen.averstad@hemcheck.com

About FIND

FIND is a global non-profit organization driving innovation in the development and delivery of diagnostics to combat major diseases affecting mainly the world’s poorest populations. FIND has a strategic collaboration with WHO and partners with global actors such as Bill & Melinda Gates Foundation, EU and USAID.

Read more at https://www.finddx.org/

About Hemcheck

Hemcheck Sweden AB, founded in 2010, produces and commercializes a patented CE-marked concept for point of care hemolysis detection. The concept consists of disposable tests as well as readers that can very quickly, directly upon sampling, identify hemolysed blood samples in vacuum tubes and blood gas syringes. Hemolysis, ruptured red blood cells, is the most common reason globally why blood samples cannot be analyzed accurately and is also a biomarker for acute medical conditions. Hemcheck’s goal is to contribute to improved healthcare by offering user-friendly solutions for the detection of hemolysed blood samples in direct connection with blood sampling near the patient. By doing so, Hemcheck can contribute to increased patient safety, more efficient processes and lower costs. The company is listed on the Nasdaq First North Growth Market.

FNCA Sweden AB, 08-528 00 399, info@fnca, is the Certified Adviser to the company.